FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387033006> ?p ?o ?g. }

• W4387033006 abstract "Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens. In animal studies and short-term human use, tedizolid lacks the hematologic and neurologic toxicity of the other available oxazolidinone, linezolid. However, there are limited prospective safety data. We conducted an open-label, non-comparative trial of oral tedizolid for BJI treatment. Primary outcomes were safety and cure rate. Eligible patients had a BJI caused by documented or suspected Gram-positive pathogen, required 4-12 weeks of therapy, and did not have myelosuppression or peripheral/optic neuropathy. Subjects underwent weekly evaluation for cytopenias and neuropathy. We enrolled 44 subjects; five were lost to follow-up. Two subjects did not complete planned treatment because of rash (n = 1) and urgent surgery (n = 1). Of 37 patients with evaluable outcomes, 17 (46%) had hardware-associated infection, 13 (35%) had osteomyelitis, 5 (14%) had prosthetic joint infection, and 2 (5%) had other BJIs. Median (mean, range) treatment duration was 12 (10.1, 4-12) weeks. There were no cases of cytopenias or peripheral or optic neuropathy. Treatment cure occurred in 13 (35%); 19 (51%) required antibiotic continuation after 12 weeks of tedizolid related to retained hardware at the BJI site, and failure occurred in four (11%), two unlikely, one possibly, and one probably due to tedizolid. We found that oral tedizolid was well tolerated for prolonged BJI treatment without significant toxicity. Clinical failure rate was similar to that of other published BJI investigations. (This study has been registered at Clinicaltrials.gov under identifier NCT03009045.) IMPORTANCE Bone and joint infections are common infections with limited effective and safe oral options for Gram-positive infections. The largest prospective clinical trial of tedizolid therapy for bone and joint infections enrolled 44 patients and tested each in person weekly with detailed safety monitoring including tests for leukopenia, anemia, thrombocytopenia, peripheral neuropathy, and optic neuropathy for up to 12 weeks. Findings demonstrated tedizolid was generally well tolerated and there were no incident cases of cytopenias or neuropathy. Cure rates were similar to that in other bone and joint infection studies. In summary, oral tedizolid appears to be a well-tolerated oral option for Gram-positive bone and joint infections." @default.
• W4387033006 created "2023-09-27" @default.
• W4387033006 creator A5004300224 @default.
• W4387033006 creator A5006551222 @default.
• W4387033006 creator A5010763789 @default.
• W4387033006 creator A5016777889 @default.
• W4387033006 creator A5031347129 @default.
• W4387033006 creator A5034375136 @default.
• W4387033006 creator A5037868773 @default.
• W4387033006 creator A5054036888 @default.
• W4387033006 creator A5062730714 @default.
• W4387033006 creator A5087805885 @default.
• W4387033006 creator A5089893702 @default.
• W4387033006 date "2023-09-26" @default.
• W4387033006 modified "2023-09-27" @default.
• W4387033006 title "Safety and tolerability of tedizolid as oral treatment for bone and joint infections" @default.
• W4387033006 cites W1674662420 @default.
• W4387033006 cites W1921639559 @default.
• W4387033006 cites W2069030485 @default.
• W4387033006 cites W2111154593 @default.
• W4387033006 cites W2124042548 @default.
• W4387033006 cites W2150199603 @default.
• W4387033006 cites W2157783283 @default.
• W4387033006 cites W2167792428 @default.
• W4387033006 cites W2170650380 @default.
• W4387033006 cites W2287532490 @default.
• W4387033006 cites W2884161307 @default.
• W4387033006 cites W2912673401 @default.
• W4387033006 cites W2914477527 @default.
• W4387033006 cites W2954072379 @default.
• W4387033006 cites W2990318328 @default.
• W4387033006 cites W3016665071 @default.
• W4387033006 cites W3080780254 @default.
• W4387033006 cites W3114169126 @default.
• W4387033006 cites W3119598592 @default.
• W4387033006 cites W3178561209 @default.
• W4387033006 cites W4281295803 @default.
• W4387033006 cites W4293764300 @default.
• W4387033006 doi "https://doi.org/10.1128/spectrum.01282-23" @default.
• W4387033006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37750695" @default.
• W4387033006 hasPublicationYear "2023" @default.
• W4387033006 type Work @default.
• W4387033006 citedByCount "0" @default.
• W4387033006 crossrefType "journal-article" @default.
• W4387033006 hasAuthorship W4387033006A5004300224 @default.
• W4387033006 hasAuthorship W4387033006A5006551222 @default.
• W4387033006 hasAuthorship W4387033006A5010763789 @default.
• W4387033006 hasAuthorship W4387033006A5016777889 @default.
• W4387033006 hasAuthorship W4387033006A5031347129 @default.
• W4387033006 hasAuthorship W4387033006A5034375136 @default.
• W4387033006 hasAuthorship W4387033006A5037868773 @default.
• W4387033006 hasAuthorship W4387033006A5054036888 @default.
• W4387033006 hasAuthorship W4387033006A5062730714 @default.
• W4387033006 hasAuthorship W4387033006A5087805885 @default.
• W4387033006 hasAuthorship W4387033006A5089893702 @default.
• W4387033006 hasBestOaLocation W43870330061 @default.
• W4387033006 hasConcept C126322002 @default.
• W4387033006 hasConcept C134018914 @default.
• W4387033006 hasConcept C141071460 @default.
• W4387033006 hasConcept C197934379 @default.
• W4387033006 hasConcept C2778375690 @default.
• W4387033006 hasConcept C2778496288 @default.
• W4387033006 hasConcept C2778570526 @default.
• W4387033006 hasConcept C2779901536 @default.
• W4387033006 hasConcept C2780551157 @default.
• W4387033006 hasConcept C29730261 @default.
• W4387033006 hasConcept C555293320 @default.
• W4387033006 hasConcept C71924100 @default.
• W4387033006 hasConceptScore W4387033006C126322002 @default.
• W4387033006 hasConceptScore W4387033006C134018914 @default.
• W4387033006 hasConceptScore W4387033006C141071460 @default.
• W4387033006 hasConceptScore W4387033006C197934379 @default.
• W4387033006 hasConceptScore W4387033006C2778375690 @default.
• W4387033006 hasConceptScore W4387033006C2778496288 @default.
• W4387033006 hasConceptScore W4387033006C2778570526 @default.
• W4387033006 hasConceptScore W4387033006C2779901536 @default.
• W4387033006 hasConceptScore W4387033006C2780551157 @default.
• W4387033006 hasConceptScore W4387033006C29730261 @default.
• W4387033006 hasConceptScore W4387033006C555293320 @default.
• W4387033006 hasConceptScore W4387033006C71924100 @default.
• W4387033006 hasLocation W43870330061 @default.
• W4387033006 hasLocation W43870330062 @default.
• W4387033006 hasOpenAccess W4387033006 @default.
• W4387033006 hasPrimaryLocation W43870330061 @default.
• W4387033006 hasRelatedWork W112819031 @default.
• W4387033006 hasRelatedWork W1605431033 @default.
• W4387033006 hasRelatedWork W2127180214 @default.
• W4387033006 hasRelatedWork W2137432312 @default.
• W4387033006 hasRelatedWork W2371615325 @default.
• W4387033006 hasRelatedWork W2468742732 @default.
• W4387033006 hasRelatedWork W2480155873 @default.
• W4387033006 hasRelatedWork W2601458346 @default.
• W4387033006 hasRelatedWork W2896565415 @default.
• W4387033006 hasRelatedWork W4286110999 @default.
• W4387033006 isParatext "false" @default.
• W4387033006 isRetracted "false" @default.
• W4387033006 workType "article" @default.